title: Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
abstract: Elevation of serum lipoprotein (a) (Lp[a]) is a known risk factor predisposing to cardiovascular and cerebrovascular disease. However, little is known about the role of increased Lp(a) in venous thromboembolism (VTE). This study evaluated the role of Lp(a) among a panel of established hereditary thrombogenic defects in patients with VTE. A total of 685 consecutive patients with at least one episode of VTE and 266 sex- and age-matched healthy controls were screened with regard to activated protein C resistance, protein C, protein S, and antithrombin deficiency, elevated serum levels of Lp(a), and the factor V G1691A, MTHFR C677T, and prothrombin G20210A mutations. Elevated Lp(a) levels above 30 mg/dL were found in 20% of all patients, as compared to 7% among healthy controls (P <.001, odds ratio [OR] 3.2, 95% confidence interval [CI], 1.9-5.3). The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7). No other established prothrombotic risk factor was found to be significantly combined with increased Lp(a). These data suggest that Lp(a) concentrations greater than 30 mg/dL are a frequent and independent risk factor for VTE. Furthermore, elevated Lp(a) levels might contribute to the penetrance of thromboembolic disease in subjects being affected by other prothrombotic defects, such as FV G1691A mutation.
authors.affiliation: Department of Hematology/Oncology, Hannover Medical School, Hannover, Germany. depka.mario@mhhannover.de
authors.forename: M
authors.initials: M
authors.lastname: von Depka
authors.forename: U
authors.initials: U
authors.lastname: Nowak-Göttl
authors.forename: R
authors.initials: R
authors.lastname: Eisert
authors.forename: C
authors.initials: C
authors.lastname: Dieterich
authors.forename: M
authors.initials: M
authors.lastname: Barthels
authors.forename: I
authors.initials: I
authors.lastname: Scharrer
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: S
authors.initials: S
authors.lastname: Ehrenforth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004252:DNA Mutational Analysis; D005165:Factor V / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D016555:Matched-Pair Analysis; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008875:Middle Aged; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000209:etiology* / Q000235:genetics; D019851:Thrombophilia / Q000097:blood / Q000235:genetics; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology* / Q000235:genetics
chemical_list: D017270:Lipoprotein(a); D005165:Factor V; D011516:Prothrombin; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2)